Antiemetic effectiveness and safety of aprepitant in patients with lung cancer receiving combination therapy with carboplatin.
Not Applicable
- Conditions
- lung cancer
- Registration Number
- JPRN-UMIN000010018
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 134
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with severe complications. Patients with nausea and vomitting in the 24 hours before chemotherapy. Patients received antiemetic therapy in the 48 hours before chemotherapy. Patients with a risk of vomitting for other reasons. (active peptic ulcer and gastrointestinal obstruction, etc)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method